American Association of Endocrine SurgeonMiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors
Section snippets
Serum samples
Fasting serum samples from patients with adrenocortical neoplasms were obtained the day of operation and stored at −80°C. Demographic, clinical, and pathologic information and tissue samples were collected under an institutional review board–approved protocol. Clinical characteristics of the study cohort are summarized in the Table. Tumors were classified as ACC if the Weiss criteria was ≥3. Tumors were classified as benign if the Weiss criteria was <3.
Serum miRNA extraction
MiRNA was extracted from serum using the
Results
Five miRNAs were measured in serum samples from patients with adrenocortical neoplasms. All 5 miRNAs were detected in serum and were normalized to miR-16, a miRNA that is present ubiquitously in serum.16 There were greater levels of miR-34a (P = .001) and miR-483-5p (P = .011) in patients with ACC (Fig 1). Mir-let-7d (P = .1975), miR-214 (P = .1370), and miR-195 (P = .9210) levels in serum were not different between patients with malignant and benign adrenocortical neoplasms (Fig 1). To
Discussion
To the authors’ knowledge, there have been no studies evaluating miRNAs levels in serum samples of patients with ACC. We showed that selected miRNAs that are dysregulated in adrenocortical neoplasms are detectable in human serum samples. Moreover, miR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors. Furthermore, we found that miR-34a and miR-483-5p were secreted by ACC cells. These miRNAs are dysregulated in ACC and could
References (18)
- et al.
The molecular basis of adrenocortical cancer
Cancer Genet
(2012) - et al.
Extracellular microRNA: a new source of biomarkers
Mutat Res
(2011) - et al.
Dysregulation of microRNAs in adrenocortical tumors
Mol Cell Endocrinol
(2012) - et al.
Tumor cell-derived exosomes: a message in a bottle
Biochim Biophys Acta
(2012) - et al.
Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study
Ann Surg
(2009) Clinical review: diagnosis and treatment of subclinical hypercortisolism
J Clin Endocrinol Metab
(2011)NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”)
NIH Consens State Sci Statements
(2002)- et al.
Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group
World J Surg
(2001) - et al.
Serum microRNAs are promising novel biomarkers
PLoS One
(2008)
Cited by (73)
The potential role of miRNAs in the pathogenesis of adrenocortical carcinoma – A focus on signaling pathways interplay
2023, Pathology Research and PracticeGenomics of benign adrenocortical tumors
2019, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :A subset of these markers can be measured by non-invasive techniques. For instance somatic mutations may be detected in circulating tumor DNA [11,12], and specifically up-regulated miRNAs [13–15] may be detected in blood. Such approaches may help to detect these diseases.
Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy
2019, Journal of BiotechnologyResearch progress and perspectives of noncoding RNAs in adrenocortical carcinoma A review
2024, Medicine (United States)Advances in translational research of the rare cancer type adrenocortical carcinoma
2023, Nature Reviews Cancer
Supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.